Cancer has no borders. Neither do we.

We transcend borders, time zones, and especially the status quo to develop therapies that are more accessible to people around the world.

Learn More

We transcend borders, time zones, and especially the status quo to develop therapies that are more accessible to people around the world.

Learn More

Putting Patients First

We offer resources to help patients and their loved ones navigate some of the complex challenges that follow the words, “You have cancer.”

Learn More
elder_women

Science-Based, Passion-Driven

We are advancing an innovative, high-value product portfolio for patients globally.

Learn More
doctor_and_patient

Passion with Purpose

We work to benefit patients wherever they live by uniting worldwide talent and resources with our vision.

Learn More
people_walking

BeiGene News

June 21, 2022

BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab

Read more

June 13, 2022

BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets

Read more

June 13, 2022

BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL

Read more

June 10, 2022

China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer

Read more

June 10, 2022

BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress

Read more

June 8, 2022

BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Read more